And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda has a few hopeful highlights. We plan to hang with our short person, catch up on our reading, watch a moving picture, and visit the Pharmalot ancestors. We will have more time to indulge, since this will be a long weekend to observe dead Presidents, which means we will return to you on Tuesday. Meanwhile, what will you be doing? This is a fine time to ready your taxes. Remember, Uncle Sam wants you … to pay up. Maybe this is an opportunity to connect with someone special or take stock of life. Or you could contact your congressional representative and urge them to send thoughts and prayers for the latest mass shooting victims. Well, whatever you do, be safe. Enjoy, and see you soon …

The Food and Drug Administration wants to let drug makers test Alzheimer’s disease treatments on patients years before the disease shows outward signs, and could approve the therapies based on subtle biological signals rather than proof they alleviate symptoms, Bloomberg News notes. The agency loosened the standard for drug makers to move ahead in a draft guidance that cuts a line from a 2013 policy calling for “widespread evidence-based agreement in the research community” about the right biological signal.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy